- 卵巢支持-间质细胞瘤
- 山东省疼痛研究会简介
- 关于调整与增补山东省疼痛研究会...
- 山东省微量元素科学研究会妇产科...
- 山东省疼痛研究会妇产科专业委员...
- Ku70在卵巢浆液性肿瘤组织中...
- 卵巢肿瘤专题会议通知
- 这几个网站到底是真还是假
- 关于公布山东省疼痛研究会妇产科...
- 又是一年一度的中国式晋升
- 子宫内膜癌微创技术专题研讨会会...
- 术后早期炎性肠梗阻的诊治
- RUNX3 Gene Meth...
- 中年的回首
- 山东省疼痛研究会妇产科专业委员...
- 山东省微量元素科学研究会妇产科...
- 多彩的表观遗传学-colour...
- 与妇科手术有关的围手术期抗凝问...
- 医生是怎样的人
- “明月松间照,清泉石上流”
- 微量元素科学研究与妇产科学
- 山东省微量元素科学研究会妇产科...
- 山东省疼痛研究会妇产科专业委员...
- RASSF1A基因甲基化与妇科...
- 卵巢支持-间质细胞瘤
- Wnt Signaling P...
- TGFß BMP ...
- Signal Transduc...
- PI3K-AKT Signal...
- p53 Signaling P...
- Oxidative Stres...
- NFkB Signaling ...
- MAP Kinase Sign...
- Extracellular M...
- DNA Damage Sign...
- Cancer PathwayF...
- Cancer Drug Res...
- Apoptosis
- Angiogenesis
- Role of vascula...
- Expression of t...
- 围手术期抗凝
- 轻松转身
- HPV与子宫颈癌的有关数据
- 与直肠癌手术有关的直肠阴道瘘(...
- Advances on VEG...
- 肾移植后全身性并发症
- 子宫颈癌:从被动防御到主动出击
- 子宫内膜癌:或许不过分干预最好...
- Delay In Diagno...
- 手术Apgar评分
- 年轻子宫内膜癌患者保留卵巢:生...
- 化疗相关性手足综合征
- 多发性子宫肌瘤是否要开刀?
- RUNX3 gene meth...
- 上皮性卵巢癌患者生育功能的保留
- 卵巢恶性生殖细胞肿瘤保留生育功...
- 子宫内膜癌保留生育功能治疗的有...
- 宫颈癌的保守性或保留子宫的手术
- Expression of E...
- 陈述
- 系统性盆腔及腹主动脉旁淋巴结清...
- 淋巴结清扫术或无助于改善晚期卵...
- The Future of P...
- Expression and ...
- Clinical implic...
- Discussion of P...
- 妇科肿瘤保留生理与生育功能的考...
- 卵巢恶性上皮性肿瘤保留生育功能...
- 剂量强度是否是治疗卵巢癌的决定...
- 多囊卵巢综合征现代治疗措施
- 节育器取出的并发症
- 多囊卵巢综合征(PCOS)的治...
- 保留子宫动脉上行支子宫切除术
- 血小板及血小板衍化生长因子与卵...
- 子宫切除对卵巢功能的影响
- 卵巢癌筛查人群的定位
- 卵巢癌的筛查
- 补片在子宫切除术后阴道脱垂盆底...
- 如何看待基因治疗
- 子宫内膜癌的手术治疗
- 晚期或复发性子宫颈癌的治疗
- 子宫颈癌的手术治疗
- 子宫内膜异位症所致疼痛的手术治...
- 子宫腺肌病
- RASSF1A基因甲基化与妇科...
- RASSF1A基因甲基化与妇科...
- HIV/AIDS诊治规范
- HIV/AIDS诊治规范
- 性传播疾病诊治规范
- 性传播疾病诊治规范
- 妇科炎症诊治规范(二)
- 妇科炎症诊治规范(二)
- 妇科炎症诊治规范(一)
- 妇科炎症诊治规范(一)
- 子宫血管瘤
- 骶前出血
- Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines
- 作者:张师前|发布时间:2009-10-21|浏览量:747次
Cancer-testis antigen (CTA), a type of protein restrictively expressed in the testes and malignant tumors, is considered to be associated with the cell carcinogenesis. Hence, CTA is thought to be an ideal target for cancer immunotherapy and has gained extensive attention in these years [1]. MAGE, GAGE and BAGE family genes, all of which are members of CTA, are expressed not only in melanoma cells, but also in many tumor tissues. Moreover, their expression is closely related to the occurrence, development and prognosis of cancer. The antigens encoded by these genes can be recognized by the body’s immune cells and can then induce the body to produce specific humoral and cellular immunity. It has been reported that MAGE, GAGE, and BAGE genes, as well as their products, could be used for molecular diagnosis and immunotherapy of tumors [2]. In recent years, the diagnosis and treatment of ovarian cancers have improved, but the long-term survival rate, especially the survival rate for advanced cases, still has not been markedly increased. Therefore, it is very important to search for tumor-specific antigen (TSA) and tumor-associated antigen (TAA) to ensure the early detection, early diagnosis and early treatment of ovarian cancer. Domestic and international scholars have conducted a great deal of research on the gene expression profiles, functions and mechanisms of MAGE, BAGE and GAGE. However, research on the role of these genes in ovarian cancer has been sparse. In the present work, the mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE was analyzed by reverse transcription polymerase chain reaction (RT-PCR), and the feasibility of their gene products as ovarian cancer markers and immunotherapy targets was also evaluated. 山东大学齐鲁医院妇科张师前
Materials and Methods
1. Cell culture
Ovarian cancer cell lines SKOV3, A2780 and COC1 were established in China. SKOV3, COC1 and normal ovarian epithelial cells (NOEC) were provided by the Bioengineering Center of Qilu Hospital, Shandong University. Melanoma cell lines MEL526, a positive control, were kindly given by Dr. Takesako. Cells were cultured in RPMI 1640 culture medium (containing 10% fetal calf serum, 100 u/ml penicillin and 100 u/ml streptomycin) at 37℃ with 5% CO2 certain humidity condition. The cells were collected by conventional digestion and stored at -80℃ when they reached about 80% confluence.
2. Clinical data and tissue samples
Patients who visited the Gynecology service of Qilu Hospital, Shandong University between January 2005 and December 2008 were selected. There were 14 cases of normal ovarian tissues, 20 cases of ovarian benign tumor samples, 47 cases of ovarian cancer samples and 7 cases of ovarian cancer metastasis samples. The obtained tissues were confirmed by histopathological examination and stored in liquid nitrogen at 10 min after surgery. The patients’ clinical data were recorded in detail. Tumor histological grades and clinical stages were evaluated according to the pathological results after surgery. The clinical stages of ovarian cancer were based on FIGO (presented in 2000) staging criteria. Of the 47 cases of ovarian cancer, there were 18 cases with serous cystadenocarcinoma, 13 cases with mucinous cystadenocarcinoma, 6 cases with endometrial carcinoma, 4 cases with clear cell tumors and 6 cases with ovarian metastatic tumors. There were 4 cases that were Stage I, 9 cases that were Stage, 30 cases in Stages Ⅲ[and 4 cases in Stage Ⅳ . With regards to histological grade, 6 cases were in G1, 24 cases were in G2 and 17 cases were in G3. There were 24 patients with ascites and 23 patients without ascites. Lymph node metastasis occurred in 21 cases but not in the other 26 cases. The patients were between 23 and 67 years of age, with an average age of 45.7 years.
3. Determination of mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE gene
Total RNA was extracted with Trizol (Shanghai Bio-Engineering Company) from various cell lines and tissue samples. A260 and A280 of total RNA were measured by UV-spectrophotometer. To synthesize the first strand of CDNA, 4 µg of RNA was reverse-transcribed with the reverse transcriptase M-MLV using Oligo dT (Shanghai Bio-Engineering Company) as the downstream primer. PCR primers were designed on different exons to ensure the specificity of amplification and to avoid genomic DNA contamination. The primers are listed in Table 1.
The PCR program was as follows. MAGE-1 and β-actin: 35 cycles of denaturation at 94℃ for 45 sec, annealing at 55℃ for 45 sec and extension at 72℃ for 1 min; MAGE-3: 40 cycles of denaturation at 94℃ for 1 min, annealing at 66℃ for 1 min 15 sec and extension at 72℃ for 1 min; GAGE-1,2: 30 cycles of denaturation at 94℃ for 1 min, annealing at 56℃ for 2 min and extension at 72℃ for 3 min; and BAGE: 30 cycles of denaturation at 94℃ for 1 min, annealing at 60℃ for 2 min and extension at 72℃ for 2 min. The PCR program was started with pre-denaturation at 94℃for 5 min and ended with a final 72℃ extension for 5 min. The PCR products were separated by electrophoresis on a 1.5 % agarose gel, stained with ethidium bromide and observed with UV lamp. Results were determined by quantification with a JD801 Image Analysis system 3.3. The melanoma cell lines MEL526 were a positive control, the sample without M-MLV reverse transcriptase was a negative control, and β-actin was an internal control for the RT-PCR. According to the sequences in GenBank, the length of PCR products for MAGE-1, MAGE-3, GAGE-1/2 and BAGE genes were 485 bp, 724 bp, 243 bp and 284 bp, respectively.
4. Statistical analysis
All analyses were performed with SPSS 10.0 software. The measurement data were analyzed with the t-test, while the comparison of menopause, pathological features (such as tumor histological type and clinical stage) and gene expression were analyzed with the χ2 test. Statistical differences were defined as P < 0.05.
Results
1. mRNA expression of MAGE, GAGE and BAGE in ovarian cancer cell lines
The mRNA expression profiles of MAGE, GAGE and BAGE in ovarian carcinoma cell lines SKOV3, A2780 and COC1 were varied, but there was at least one gene expressed in each cell line. In SKOV3 (Figure 1), MAGE-1 was expressed (line 2, a band ranging between 400-500 bp). In A2780 (Figure 2), MAGE-1 (line 2, a band ranging between 400-500 bp), MAGE-3 (line 3, a band ranging between 700-800 bp) and GAGE-1/2 (line 5, a band ranging between 200-300 bp) were expressed. In COC1 (Figure 3), MAGE (line 2, a band ranging between 400-500 bp) and MAGE-3 (line 3, a band ranging between 700-800 bp) were expressed.
2. mRNA expression of MAGE, GAGE and BAGE in various ovarian cancer tissues
MAGE, GAGE and BAGE genes were not expressed in normal ovarian tissue. In benign tumors, only the MAGE gene was expressed, and the positive rate was 15% (3/20). In ovarian cancer tissues, MAGE-1 and MAGE-3 were highly expressed with expression rates of 51.1% (25/47) and 34% (16/47), while GAGE-1 / 2 and BAGE had relatively low expression rates of 25.5% (12/47) and 14.9% (7/47). In ovarian cancer metastases, only MAGE-1 and BAGE were expressed with expression rates of 28.6% (2/7) and 14.3% (1/7) (Table 2 & Figure 4).
3. The relationship between the pathological types of ovarian cancer and the positive expression rates of MAGE, GAGE and BAGE
In serous cystadenocarcinoma samples, the positive expression rate of MAGE-1 and MAGE-3 was 77.8% (14/18) and 66.7% (12/18), which was significantly higher than that in other types of ovarian cancer (P < 0.05). Although the expression of GAGE-1/2 and BAGE was low in ovarian cancer tissues, their positive expression rates were relatively high in serous cystadenocarcinomas (Table 3).
4. The correlation between the pathological features of ovarian cancer and the positive expression rates of MAGE, GAGE and BAGE
Clinical data of ovarian cancer patients with or without MAGE, GAGE or BAGE expression were analyzed. The expression of MAGE, GAGE and BAGE was not correlated with menopause or lymph node metastasis (P > 0.05). Positive expression of MAGE-1 and MAGE-3 was positively correlated with the pathological grade and clinical stage of ovarian cancer patients (P < 0.05), while positive expression of MAGE-1 and MAGE-3 was not related to pathological grade and clinical stage (P > 0.05). Additionally, ascites was correlated with the expression of BAGE, as indicated by the fact that the positive expression rate of BAGE was significantly higher in ovarian cancer patients with ascites (P < 0.05) (Table 4).
Discussion
At present, 23 members have been found in the MAGE gene family. They are located on the human X chromosome and are highly expressed in a variety of tumors. The proteins encoded by these genes contain more than 300 amino acids, and peptides processed from these proteins can bind to all types of human leukocyte antigens to form complexes, which can be recognized by autologous T-lymphocytes. The GAGE gene family contains at least eight near-source genes, which are all located on the human X chromosome. Antigen peptide YRPRPRRY encoded by the GAGE-1 gene and GAGE-2 gene could interact with HLA-Cw*0601 to form a complex, which may be recognized by activated cytotoxic T-lymphocyte [3]. In addition to the several BAGE-family members that were found previously, another five new BAGE genes have been discovered and are located adjacent to the centromere of chromosome 13 or 21. Additionally, there are nine BAGE gene segments located adjacent to the centromere of chromosomes 9, 13, 18 or 21. These genes and gene segments are highly homologous (90%-99%). Polypeptides encoded by BAGE genes contain 43 amino acids, whose AARAVFLAL fragment interacts with HLA-Cw*1601 and is then recognized by activated cytotoxic T lymphocytes.
MAGE, BAGE, and GAGE proteins are processed to peptides in cancer cells by low molecular weight polypeptide (LMP) and are then transported to the lumen of the endoplasmic reticulum by transporter associated with antigen processing (TAP). The antigen peptides interact with MHC I molecules to form complexes, which are expressed on the surface of tumor cells via the Golgi apparatus. CTL can recognize the surface complexes through T cell antigen receptor (TCR) interactions and can destroy the tumor cells through a killing mechanism. Therefore, MAGE, BAGE, and GAGE genes, as well as their products have wide application prospects in tumor-specific initiative immunotherapy [4].
Many tumor marker studies have shown that BAGE, MAGE-1/3 and GAGE-1/2 are expressed in the majority of different types of ovarian cancer, while not in the normal ovarian tissue or body fluids. Russo et al. [5] detected transcription levels of MAGE-1 and MAGE-3 in 54 patients with epithelial ovarian cancer using the RT-PCR method. Their results showed that the expression rates of MAGE-1, MAGE-3, BAGE and GAGE were 28%, 17%, 15% and 31%, respectively. Moreover, they reported that an increase in the expression rate of MAGE-1 was found with the increase in tumor clinical stage, as indicated by the fact that the expression rate of MAGE-1 in Stage III and Stage IV of ovarian cancer was 22% and 43%, respectively. Gillespie et al. [6] found that the expression rate of MAGE-1 in ovarian cancer was 56%, while the expression rates of MAGE-2, -3, -4, BAGE and GAGE were relatively low. Hofmann et al. [3] obtained ascites samples obtained by fine-needle aspiration and found that BAGE, MAGE-1, MAGE-3 and GAGE-1/2 mRNA was positively expressed in 56% (15/27), 7% (2/27), 30% (8/27) and 30% (8/27) of samples, respectively. The sensitivity was 94%; the specificity was 94%; and in one case, there was a false positive when these genes were jointly detected in ascites samples. Therefore, the detection of BAGE, GAGE, and MAGE mRNA in ovarian cancer ascites may be a potential diagnostic option.
In our study, MAGE, GAGE and BAGE genes were not expressed in normal ovarian tissue, only the MAGE-1 gene was expressed in benign tumors at a rate of 15% (3/20). In ovarian cancer tissues, MAGE-1 and MAGE-3 genes were highly expressed with a positive rate of 51.1% (25/47) and 34% (16/47). The expression rate of the MAGE-1 gene was slightly lower than that reported by Gillespie et al. [6]. The expression rates of the GAGE-1/2 and BAGE gene in ovarian cancer were 25.5% (12/47) and 14.9% (7/47), respectively, which were significantly higher than that reported by Gillespie et al. [6]. In cancer metastasis outside the ovary, only the MAGE-1 and BAGE gene were expressed, with positive expression rates of 28.6% (2/7) and 14.3% (1/7), respectively. The positive rates of MAGE-1 and MAGE-3 genes in serous adenocarcinoma were significantly higher than that in other types of ovarian cancer (P < 0.05).
Further statistical analyses of MAGE, GAGE and BAGE gene expression, as well as the clinical data from 47 cases of ovarian cancer were further conducted. Our results demonstrated that gene expression was not correlated with menopause or lymph node metastasis, and MAGE-1 and MAGE-3 gene expression was closely related to cell differentiation and cancer clinical stage (P <0.05). The lower the histological grade, the later the clinical stage, and the higher the expression rates of MAGE-1 and MAGE-3 genes. Therefore, MAGE-1 and MAGE-3 genes were closely related to the degree of malignancy and prognosis of the ovarian cancer; thus, the two could be used as independent prognostic indicators for ovarian cancer. The positive rate of BAGE was higher in ovarian cancer patients with ascites (P <0.05), which was consistent with the finding of Hofmann et al. [3] that BAGE mRNA was positively expressed in 56% of ovarian cancer patients with ascites. These data suggested that BAGE may be associated with the formation and development of ascites. In addition, MAGE, GAGE and BAGE genes were expressed in ovarian cancer cell lines SKOV3, A2780 and COC1, which further demonstrated the role of these genes in ovarian cancer diagnoses. It was reported that the vaccine manufactured by using MAGE gene products had an acceptable toxicity and displayed a good effect on tumor response in the absence of other therapy [7]. The MAGE-3 gene has been used as a reliable indicator to detect melanoma cells in peripheral blood in the Gene Chip studies, as well as to monitor the infiltrative growth of tumor cells, thus, allowing for the determination of appropriate treatment interventions [8].
The products of the MAGE, BAGE and GAGE family genes are tumor-specific antigens that are highly expressed in different histological types of tumors. Therefore, these genes have drawn much attention for tumor immunotherapy. Currently, the most common application of MAGE, BAGE and GAGE genes in the ovarian cancer vaccine is the peptide vaccine and DC vaccine [9]. Although recent studies of these genes, especially the MAGE genes, have been conducted by domestic and international scholars and have resulted in new insight into these genes, our understanding of these genes is still insufficient. Due to the heterogeneity of tumor cells, the expression of MAGE, BAGE and GAGE family members may be varied in different types of ovarian tumors or in different parts of the same tumor, and it is very difficult to choose a target antigen for immunotherapy [10]. Through the present work, we believe that the question of whether MAGE, BAGE and GAGE genes could be useful as molecular markers and tumor-specific immunotherapy target sites for ovarian cancer still requires more in-depth investigation.
TA的其他文章: